Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks
Publication in refereed journal


Times Cited
Web of Science18WOS source URL (as at 25/06/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractAims We investigated the therapeutic efficacy of thrombopoietin (TPO) in acute and chronic rat models of heart damage and explored the mechanisms in terms of genome-wide transcriptional changes, phosphorylation signals, and bone marrow endothelial progenitor cell (EPC) levels.
All Author(s) ListChan KYY, Xiang P, Zhou LG, Li KR, Ng PC, Wang CC, Zhang L, Deng HY, Pong NH, Zhao HL, Chan WY, Sung RYT
Journal nameEuropean Journal of Heart Failure
Detailed descriptiondoi:10.1093/eurjhf/hfr001.\n\nTo ORKTS: doi:10.1093/eurjhf/hfr001
Year2011
Month4
Day1
Volume Number13
Issue Number4
PublisherOXFORD UNIV PRESS
Pages366 - 376
ISSN1388-9842
eISSN1879-0844
LanguagesEnglish-United Kingdom
KeywordsAKT activation; Doxorubicin-induced cardiomyopathy; Endothelial progenitor cells; Expression profiling; Thrombopoietin
Web of Science Subject CategoriesCardiac & Cardiovascular Systems; CARDIAC & CARDIOVASCULAR SYSTEMS; Cardiovascular System & Cardiology

Last updated on 2020-26-06 at 00:18